NO332991B1 - Kalsiumreseptormodulerende forbindelse, farmasoytisk sammensetning og anvendelse derav - Google Patents

Kalsiumreseptormodulerende forbindelse, farmasoytisk sammensetning og anvendelse derav

Info

Publication number
NO332991B1
NO332991B1 NO20051328A NO20051328A NO332991B1 NO 332991 B1 NO332991 B1 NO 332991B1 NO 20051328 A NO20051328 A NO 20051328A NO 20051328 A NO20051328 A NO 20051328A NO 332991 B1 NO332991 B1 NO 332991B1
Authority
NO
Norway
Prior art keywords
salt
pyrimidine
ethyl
carboxamide
propyl
Prior art date
Application number
NO20051328A
Other languages
English (en)
Norwegian (no)
Other versions
NO20051328L (no
Inventor
Tsuneo Yasuma
Albert Charles Gyorkos
Hiroyuki Kimura
Akira Mori
Masahiro Kawase
Masato Yoshida
Scott Alan Pratt
Christopher Peter Corrette
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20051328L publication Critical patent/NO20051328L/no
Publication of NO332991B1 publication Critical patent/NO332991B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20051328A 2002-08-26 2005-03-15 Kalsiumreseptormodulerende forbindelse, farmasoytisk sammensetning og anvendelse derav NO332991B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40601202P 2002-08-26 2002-08-26
US46612903P 2003-04-28 2003-04-28
PCT/US2003/026317 WO2004017908A2 (en) 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof

Publications (2)

Publication Number Publication Date
NO20051328L NO20051328L (no) 2005-03-15
NO332991B1 true NO332991B1 (no) 2013-02-11

Family

ID=31949909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051328A NO332991B1 (no) 2002-08-26 2005-03-15 Kalsiumreseptormodulerende forbindelse, farmasoytisk sammensetning og anvendelse derav

Country Status (12)

Country Link
US (3) US7514441B2 (enExample)
EP (1) EP1572113B1 (enExample)
JP (1) JP4494205B2 (enExample)
KR (1) KR101050700B1 (enExample)
AU (1) AU2003265585B2 (enExample)
BR (1) BRPI0313880B8 (enExample)
CA (1) CA2494700C (enExample)
ES (1) ES2635838T3 (enExample)
NO (1) NO332991B1 (enExample)
NZ (1) NZ538223A (enExample)
PL (1) PL382706A1 (enExample)
WO (1) WO2004017908A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265585B2 (en) * 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JPWO2007102531A1 (ja) * 2006-03-08 2009-07-23 武田薬品工業株式会社 併用薬
US8779004B2 (en) 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
US8093299B2 (en) 2007-03-30 2012-01-10 Amgen Inc. Methods of treating bowel disorders
WO2008139947A1 (ja) * 2007-05-08 2008-11-20 Ajinomoto Co., Inc. 下痢の予防又は治療剤
EP2197280B1 (en) 2007-08-27 2013-06-19 Basf Se Pyrazole compounds for controlling invertebrate pests
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101479371B1 (ko) 2008-06-05 2015-01-05 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물 및 그 용도
KR20110010781A (ko) * 2008-06-16 2011-02-07 에프. 호프만-라 로슈 아게 Nk2 수용체 길항제로서의 피롤리딘 유도체
WO2010034737A1 (en) 2008-09-24 2010-04-01 Basf Se Pyrazole compounds for controlling invertebrate pests
BRPI0919085B1 (pt) 2008-09-24 2021-05-11 Basf Se métodos não terapêuticos para controlar pragas invertebradas e para proteger material de propagação de plantas e/ou plantas que se desenvolvem dos mesmos, compostos de pirazol ou um sal ou um n-óxido dos mesmos, e, composição agrícola
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
EP2451804B1 (en) 2009-07-06 2014-04-30 Basf Se Pyridazine compounds for controlling invertebrate pests
BR112012000149B8 (pt) 2009-07-06 2021-01-12 Basf Se compostos de piridazina, método para controlar pragas invertebradas e método para proteger material de propagação de planta e/ou as plantas
US9125414B2 (en) 2009-07-24 2015-09-08 Basf Se Pyridine derivatives compounds for controlling invertebrate pests
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JP2014511894A (ja) * 2011-04-20 2014-05-19 グラクソ グループ リミテッド 抗結核化合物としてのテトラヒドロピラゾロ[1,5‐a]ピリミジン
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
CA2941206C (en) 2014-03-27 2022-09-20 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors
CA2940918C (en) 2014-03-27 2023-10-24 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists
JP6839097B2 (ja) * 2015-12-25 2021-03-03 武田薬品工業株式会社 医薬
ES2882175T3 (es) * 2016-03-28 2021-12-01 Takeda Pharmaceuticals Co Compuestos para su uso en el tratamiento de la hipertensión pulmonar
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
EA201990519A1 (ru) 2016-08-16 2019-08-30 Бейджин, Лтд. КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2018100070A1 (en) 2016-12-02 2018-06-07 F. Hoffmann-La Roche Ag Bicyclic amide compounds and methods of use thereof
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
US10919891B2 (en) 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018199236A1 (ja) * 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11072617B2 (en) 2017-10-31 2021-07-27 Genentech, Inc. Bicyclic sulfones and sulfoxides and methods of use thereof
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
EP3908586B1 (en) 2019-01-11 2022-12-21 F. Hoffmann-La Roche AG Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918074A (en) * 1984-03-12 1990-04-17 Yoshitomi Pharmaceutical Industries, Ltd. Polyazaheterocycle compounds
EP0217142A3 (en) 1985-09-30 1988-01-07 Yoshitomi Pharmaceutical Industries, Ltd. A polyazaheterocyclic compound
US4746656A (en) * 1986-07-21 1988-05-24 E. R. Squibb & Sons, Inc. 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
WO2001016138A1 (en) 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
CN1263743C (zh) 2000-01-24 2006-07-12 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
NZ540574A (en) 2001-03-14 2006-11-30 Gruenenthal Chemie Substituted thiazolopyrimidines used as analgesics
AU2003265585B2 (en) * 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof

Also Published As

Publication number Publication date
EP1572113A2 (en) 2005-09-14
PL382706A1 (pl) 2007-11-26
WO2004017908A3 (en) 2006-01-05
US20090215746A1 (en) 2009-08-27
US20060079536A1 (en) 2006-04-13
CA2494700A1 (en) 2004-03-04
CA2494700C (en) 2011-06-28
KR101050700B1 (ko) 2011-07-20
NO20051328L (no) 2005-03-15
EP1572113A4 (en) 2006-11-22
BRPI0313880B1 (pt) 2016-09-27
JP2006510582A (ja) 2006-03-30
WO2004017908A2 (en) 2004-03-04
BR0313880A (pt) 2007-11-06
NZ538223A (en) 2008-03-28
AU2003265585B2 (en) 2008-07-03
BRPI0313880B8 (pt) 2021-05-25
ES2635838T3 (es) 2017-10-05
US9447100B2 (en) 2016-09-20
US20140155416A1 (en) 2014-06-05
AU2003265585A1 (en) 2004-03-11
KR20050038641A (ko) 2005-04-27
US7514441B2 (en) 2009-04-07
EP1572113B1 (en) 2017-05-17
JP4494205B2 (ja) 2010-06-30

Similar Documents

Publication Publication Date Title
NO332991B1 (no) Kalsiumreseptormodulerende forbindelse, farmasoytisk sammensetning og anvendelse derav
US11639353B2 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
JP7299382B2 (ja) Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
MX2014013549A (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
RU2099331C1 (ru) N-замещенные гетероциклические производные или их соли, промежуточные производные пиримидина и имидазолина и фармацевтическая композиция на основе замещенных гетероциклических производных
US8338614B2 (en) Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease
EP1537114B1 (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
JP2003500404A (ja) 新たな薬学的に活性な化合物
TW200825058A (en) Cysteine protease inhibitors
EP2616070A1 (en) Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
UA124990C2 (uk) Інгібітори magl на основі піразолу
AU2008320718B2 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
US20180030030A1 (en) Amide compound
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
TW202136236A (zh) Adamts抑制劑、其製備方法及醫藥用途
US20090170830A1 (en) Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
US20090182021A1 (en) Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
US12012374B2 (en) Agonists of ROR GAMMAt
TW202523331A (zh) 作為sstr4激動劑之(2s,5r)-5-(羥甲基)嗎啉-2-甲醯胺
HK1192230A (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
US20230295087A1 (en) AGONISTS OF ROR GAMMAt
HK1192230B (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
HK1080290B (en) Organic compounds as agents for the treatment of aldosterone mediated conditions

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees